EUVIMEDEUVIMED entdecken
Crossref

Identification of a CTX-M-255 β-lactamase containing a G239S substitution selectively conferring resistance to penicillin/β-lactamase inhibitor combinations

Minna Rud Andreasen, Tim Rick, Nicolai Riff Alexandersen, Katrine Hartung Hansen, Martin Schou Pedersen, Jakob K Warweitzky, Carolina Mastella Botelho, Susanne Häussler iD, Lotte Jelsbak, Kristian Schønning iD

Journal of Antimicrobial Chemotherapy · 2024

DOI: 10.1093/jac/dkae033 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Antimicrobial Chemotherapy, 2024. Verfasst von Minna Rud Andreasen und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Science and Environment, Roskilde University, Roskilde, Denmark. Hauptthemen laut MEDLINE: beta-Lactamase Inhibitors, Anti-Bacterial Agents. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 19 Literaturangaben. Gefördert von: Novo Nordisk Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

An Escherichia coli isolate, WGS1363, showed resistance to piperacillin/tazobactam but susceptibility to cephalosporins and contained a previously unrecognized β-lactamase, CTX-M-255, as the only acquired β-lactamase. CTX-M-255 was identical to CTX-M-27 except for a G239S substitution. Here, we characterize the hydrolytic spectrum of CTX-M-255 and a previously reported β-lactamase, CTX-M-178, also containing a G239S substitution and compare it to their respective parental enzymes, CTX-M-27 and CTX-M-15.

Methods

All β-lactamase genes were expressed in E. coli TOP10 and MICs to representative β-lactam-antibiotics were determined. Furthermore, blaCTX-M-15, blaCTX-M-27, blaCTX-M-178 and blaCTX-M-255 with C-terminal His-tag fusions were affinity purified for enzyme kinetic assays determining Michaelis–Menten kinetic parameters against representative β-lactam-antibiotics and IC50s of clavulanate, sulbactam, tazobactam and avibactam.

Results

TOP10-transformants expressing blaCTX-M-178 and blaCTX-M-255 showed resistance to penicillin/β-lactamase combinations and susceptibility to cephalothin and cefotaxime in contrast to transformants expressing blaCTX-M-15 and blaCTX-M-27. Determination of enzyme kinetic parameters showed that CTX-M-178 and CTX-M-255 both lacked hydrolytic activity against cephalosporins and showed impaired hydrolytic efficiency against penicillin antibiotics compared to their parental enzymes. Both enzymes appeared more active against piperacillin compared to benzylpenicillin and ampicillin. Compared to their parental enzymes, IC50s of β-lactamase-inhibitors were increased more than 1000-fold for CTX-M-178 and CTX-M-255.

Conclusions

CTX-M-178 and CTX-M-255, both containing a G239S substitution, conferred resistance to piperacillin/tazobactam and may be characterized as inhibitor-resistant CTX-M β-lactamases. Inhibitor resistance was accompanied by loss of activity against cephalosporins and monobactams. These findings add to the necessary knowledge base for predicting antibiotic susceptibility from genotypic data.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

beta-Lactamase InhibitorsAnti-Bacterial AgentsEscherichia colibeta-LactamasesPenicillinsCephalosporinsTazobactamPiperacillinMonobactamsPiperacillin, Tazobactam Drug CombinationMicrobial Sensitivity Tests

Substanzen

beta-Lactamase InhibitorsAnti-Bacterial Agentsbeta-LactamasesPenicillinsCephalosporinsTazobactamPiperacillinMonobactamsPiperacillin, Tazobactam Drug Combination

Autor:innen und Institutionen

  • Department of Science and Environment, Roskilde University, Roskilde, Denmark.
  • Department of Clinical Microbiology, Copenhagen University Hospital-Amager and Hvidovre, Copenhagen, Denmark.
  • Department of Clinical Microbiology, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark.
  • Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.
  • Department Molecular Bacteriology, Helmholtz Centre for Infection Research, Braunschweig, Germany.
  • Twincore, Centre for Experimental and Clinical Infection Research, A Joint Venture of the Helmholtz Centre for Infection Research and the Hannover Medical School, Hannover, Germany.

ORCID-Profile: Susanne Häussler, Kristian Schønning

Förderung

  • Novo Nordisk Foundation

Zitieren

APA

Andreasen, M. R., Rick, T., Alexandersen, N. R., Hansen, K. H., Pedersen, M. S., Warweitzky, J. K., Botelho, C. M., Häussler, S., Jelsbak, L., & Schønning, K. (2024). Identification of a CTX-M-255 β-lactamase containing a G239S substitution selectively conferring resistance to penicillin/β-lactamase inhibitor combinations. Journal of Antimicrobial Chemotherapy. https://doi.org/10.1093/jac/dkae033

Vancouver

Andreasen MR, Rick T, Alexandersen NR, Hansen KH, Pedersen MS, Warweitzky JK, et al. Identification of a CTX-M-255 β-lactamase containing a G239S substitution selectively conferring resistance to penicillin/β-lactamase inhibitor combinations. Journal of Antimicrobial Chemotherapy. 2024. doi:10.1093/jac/dkae033

BibTeX
@article{Andreasen2024,
  author = {Andreasen, Minna Rud and Rick, Tim and Alexandersen, Nicolai Riff and Hansen, Katrine Hartung and Pedersen, Martin Schou and Warweitzky, Jakob K and Botelho, Carolina Mastella and Häussler, Susanne and Jelsbak, Lotte and Schønning, Kristian},
  title = {Identification of a CTX-M-255 β-lactamase containing a G239S substitution selectively conferring resistance to penicillin/β-lactamase inhibitor combinations},
  journal = {Journal of Antimicrobial Chemotherapy},
  year = {2024},
  doi = {10.1093/jac/dkae033}
}
Kostenlos starten →